cilgavimab   Click here for help

GtoPdb Ligand ID: 11329

Synonyms: AZD1061 | COV2-2130
Compound class: Antibody
Comment: Cilgavimab is a monoclonal antibody against the surface spike protein of SARS-CoV-2 [1]. It was developed by AstraZeneca. This mAb blocks spike binding to ACE2 and prevents infection in animals. It is designed to be a long-acting agent, and in combination with tixagevimab, is proposed as a therapeutic for those people who are likely to respond poorly to SARS-CoV-2 vaccines, or who cannot be vaccinated for any reason, including those who are immunocompromised.
Classification Click here for help
Compound class Antibody
International Nonproprietary Names Click here for help
INN number INN
11777 cilgavimab
Synonyms Click here for help
AZD1061 | COV2-2130
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 1106
Other databases
GtoPdb PubChem SID 434321764
Search PubMed clinical trials cilgavimab
Search PubMed titles cilgavimab
Search PubMed titles/abstracts cilgavimab